anti-CD20/CD30-CAR-T / Shanghai First Song Therap - LARVOL DELTA

Case Report: Bispecific CD20/CD30-targeted chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma. (PubMed, Front Immunol) - P1 | "The patient received two doses of anti-CD20/CD30-CAR-T therapy administered one month apart...The report underscores the promising therapeutic potential and safety profile of CD20/CD30-directed CAR T-cell therapy. https://www.clinicaltrials.gov, identifier NCT06756321."

Journal • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TNFRSF8

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Affiliated Hospital of Nantong University

New P1 trial • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology

Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects With Relapsed/Refractory Lymphoma (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Shanghai First Song Biotechnology Co., LTD

CAR T-Cell Therapy • New P1 trial • Hematological Malignancies • Lymphoma • Oncology • TNFRSF8